EDGE-Gastric Trial: Breaking Down Data for Domvanalimab/Zimberelimab Plus Chemo in First-Line Gastric/GEJ/Esophageal Adenocarcinoma

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, dissect the results from arm A1 of the phase 2 EDGE-Gastric trial evaluating domvanalimab plus zimberelimab and FOLFOX in first-line advanced gastric, GEJ, and esophageal adenocarcinoma. They outline key efficacy signals, including durability of response, and progression-free survival trends, while also commenting on the safety profile and any emerging toxicities observed with longer follow-up. They explain how these findings further strengthen the clinical rationale for this dual-checkpoint strategy in the frontline setting.